'Pfizer Says Its RSV Vaccine Will Have $295 Per Dose List Price For Maternal Use' - Reuters Citing CDC Advisory Panel Meeting
Portfolio Pulse from Benzinga Newsdesk
Pfizer has announced that its RSV vaccine will be priced at $295 per dose for maternal use, according to a CDC Advisory Panel Meeting.
September 22, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's announcement of the pricing for its RSV vaccine could potentially impact its stock price.
The pricing of a new product, especially a vaccine, can significantly impact a pharmaceutical company's revenues and thus its stock price. If the market perceives the price as fair and the vaccine as effective, this could lead to increased sales and a positive impact on Pfizer's stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100